Elzonris
Payments companies reported to CMS as associated with Elzonris. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Elzonris, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Elzonris
These are the largest totals companies reported as associated with Elzonris. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Samir Khleif | Augusta, GA | Medical Oncology | $203,375.00 |
| Thomas Leblanc | Durham, NC | Medical Oncology | $60,880.28 |
| Salman Fazal | Pittsburgh, PA | Hematology & Oncology | $52,884.10 |
| George Yaghmour | Los Angeles, CA | Hematology & Oncology | $38,356.84 |
| Sheeja Pullarkat | Los Angeles, CA | Anatomic Pathology | $31,635.92 |
| James Mccloskey | Hackensack, NJ | Medical Oncology | $29,485.79 |
| Jeffrey Schriber | Scottsdale, AZ | Hematology & Oncology | $27,605.40 |
| Hagop Kantarjian | Houston, TX | Medical Oncology | $24,000.00 |
| Serge Alexanian | Los Angeles, CA | Anatomic Pathology & Clinical Pathology | $22,955.54 |
| Miki Haraguni | Westlake Village, CA | Family | $21,940.64 |
Prescribed Elzonris?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.